The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis
Semaglutide
Clinical endpoint
DOI:
10.1007/s11695-022-06211-9
Publication Date:
2022-07-25T19:02:52Z
AUTHORS (8)
ABSTRACT
Abstract Purpose About 20–25% of patients experience weight regain (WR) or insufficient loss (IWL) after bariatric metabolic surgery (BS). Therefore, we aimed to retrospectively assess the effectiveness adjunct treatment with GLP-1 receptor agonist semaglutide in non-diabetic WR IWL BS. Materials and Methods Post-bariatric without type 2 diabetes (T2D) ( n = 44) were included analysis. The primary endpoint was 3 6 months initiation treatment. Secondary endpoints change BMI, HbA1c, lipid profile, hs-CRP, liver enzymes. Results Patients started 64.7 ± 47.6 (mean SD) At semaglutide, post-bariatric nadir 12.3 14.4% SD). Total during − 6.0 4.3% SD, p < 0.001) (3.2 months, IQR 3.0–3.5, 38) 10.3 5.5% (5.8 5.8–6.4, 20). categorical > 5% 61% patients, 10% 16% 15% 2% patients. Triglycerides (OR 0.99; 0.05), ALT 0.87; AST 0.89; 0.05) at baseline negatively associated least months’ follow-up 0.05). Conclusion Treatment options manage excess (regain) are scarce. Our results imply a clear benefit However, these need be confirmed prospective randomized controlled trial close gap between lifestyle intervention revision Graphical abstract
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (36)
CITATIONS (55)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....